Contrasting OSR (OSRH) and Its Rivals

OSR (NASDAQ:OSRH) is one of 89 publicly-traded companies in the “UNCLASSIFIED” industry, but how does it compare to its rivals? We will compare OSR to related companies based on the strength of its valuation, risk, earnings, profitability, analyst recommendations, dividends and institutional ownership.

Profitability

This table compares OSR and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
OSR	N/A	-12.19%	-8.18%
OSR Competitors	0.86%	0.95%	0.80%

Valuation & Earnings

This table compares OSR and its rivals revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
OSR	N/A	-$2.41 million	-0.66
OSR Competitors	$46.94 million	-$19.62 million	95.96

OSR’s rivals have higher revenue, but lower earnings than OSR. OSR is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Volatility & Risk

OSR has a beta of 1.41, indicating that its stock price is 41% more volatile than the S&P 500. Comparatively, OSR’s rivals have a beta of -0.08, indicating that their average stock price is 108% less volatile than the S&P 500.

Insider and Institutional Ownership

55.3% of OSR shares are owned by institutional investors. Comparatively, 52.0% of shares of all “UNCLASSIFIED” companies are owned by institutional investors. 60.6% of OSR shares are owned by insiders. Comparatively, 42.9% of shares of all “UNCLASSIFIED” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of current ratings and price targets for OSR and its rivals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OSR	1	0	0	0	1.00
OSR Competitors	213	263	217	3	2.01

As a group, “UNCLASSIFIED” companies have a potential upside of 78.46%. Given OSR’s rivals stronger consensus rating and higher possible upside, analysts clearly believe OSR has less favorable growth aspects than its rivals.

Summary

OSR rivals beat OSR on 9 of the 13 factors compared.

About OSR

OSR Holdings leverages its international network of partners in the US, Europe, and South Korea to market and license its pipeline of proprietary platform technologies for broad application to efficient clinical trial programs, with the ultimate goal of addressing unmet medical needs. We partner with biotherapeutics companies with innovative and proprietary drug R&D “platform technologies” versus “assets only” companies, whose commercial viability is heavily dependent on positive results for individual treatment modalities in extremely rigorous and time consuming clinical trials. We focus on value creation through investments and collaborations with US and EU biotech companies, with the strategic goal of expansion into South Korea (specifically) and Asia (generally). OSR Holdings is headquartered in Paju, South Korea.